Showing 4,501 - 4,520 results of 29,616 for search '(( 50 ((mean decrease) OR (((a decrease) OR (nn decrease)))) ) OR ( 12 wt decrease ))', query time: 0.85s Refine Results
  1. 4501

    Quantile regression results of male triathletes. by Junhui Zhao (626062)

    Published 2024
    “…Temperature has a positive effect on race times, while altitude also shows a significant positive impact, with race times decreasing as altitude increases (up to 1,600 meters in this study’s dataset). …”
  2. 4502

    Descriptive statistics for categorical variables. by Junhui Zhao (626062)

    Published 2024
    “…Temperature has a positive effect on race times, while altitude also shows a significant positive impact, with race times decreasing as altitude increases (up to 1,600 meters in this study’s dataset). …”
  3. 4503

    List of triathlon events analyzed. by Junhui Zhao (626062)

    Published 2024
    “…Temperature has a positive effect on race times, while altitude also shows a significant positive impact, with race times decreasing as altitude increases (up to 1,600 meters in this study’s dataset). …”
  4. 4504

    Descriptive statistics for numerical variables. by Junhui Zhao (626062)

    Published 2024
    “…Temperature has a positive effect on race times, while altitude also shows a significant positive impact, with race times decreasing as altitude increases (up to 1,600 meters in this study’s dataset). …”
  5. 4505
  6. 4506

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

    Published 2022
    “…Low-dose <b>35m</b> remarkably decreases LPS-induced IL-1β release both <i>in vitro</i> and <i>in vivo</i> by blocking the activation of NLRP3, indicating that <b>35m</b> can be a potential orally active therapeutic agent for the treatment of NLRP3-related diseases.…”
  7. 4507

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

    Published 2022
    “…Low-dose <b>35m</b> remarkably decreases LPS-induced IL-1β release both <i>in vitro</i> and <i>in vivo</i> by blocking the activation of NLRP3, indicating that <b>35m</b> can be a potential orally active therapeutic agent for the treatment of NLRP3-related diseases.…”
  8. 4508
  9. 4509
  10. 4510
  11. 4511
  12. 4512
  13. 4513
  14. 4514
  15. 4515
  16. 4516
  17. 4517
  18. 4518
  19. 4519
  20. 4520

    30-day unplanned readmission rate in otolaryngology patients: A population-based study in Thuringia, Germany by Wido Rippe (7513133)

    Published 2019
    “…Unplanned readmission had more frequently a non-surgical treatment at readmission than a surgical treatment (OR = 3.92; CI = 2.24–6.84) and needed more frequently further diagnostics (OR = 2.34; CI = 1.34–4.11). …”